Zalevsky Jonathan 4

What Happened
Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), sold 199 shares on 2026-05-19 at a weighted average price of $65.51, for total proceeds of approximately $13,036. The filing reports the transaction as a sale (code S) executed via open market or private sale.

Key Details

• Transaction date: 2026-05-19 (Form 4 filed 2026-05-21 — appears timely).
• Price: weighted average $65.51; individual trades ranged from $64.88 to $68.43 (per filing footnote).
• Shares sold: 199; proceeds ≈ $13,036.
• Reason: Footnote indicates the sale was to cover required tax withholding on vested RSUs and “does not represent a discretionary trade.” (Footnote F1)
• Additional note: The filing states the reporting person can provide full trade-by-trade details on request (Footnote F2).
• Shares owned after transaction: not specified in the provided summary — see the Form 4 for post-transaction holdings.

Context
This was a tax-withholding sale related to RSU vesting, which is routine for insiders and typically not interpreted as a signal about the executive’s view of the company. Purchases are generally more indicative of insider confidence; sales to cover taxes are common and administrative in nature.